Loading...
XKRX
214150
Market cap2.78bUSD
Jun 12, Last price  
59,700.00KRW
Name

Classys Inc

Chart & Performance

D1W1MN
P/E
39.29
P/S
15.83
EPS
1,519.59
Div Yield, %
Shrs. gr., 5y
0.40%
Rev. gr., 5y
24.53%
Revenues
242.94b
+34.87%
81,133,256,55076,460,931,510100,596,935,570141,803,242,400180,122,798,010242,938,965,370
Net income
97.88b
+31.86%
33,393,938,58938,164,823,42043,804,676,38075,378,647,24074,225,203,05097,875,278,350
CFO
102.80b
+59.06%
39,033,739,58038,125,167,92036,367,042,25054,754,505,36064,631,971,910102,800,406,880
Dividend
Dec 27, 2023116 KRW/sh
Earnings
Aug 12, 2025

Profile

CLASSYS Inc. provides medical aesthetics devices worldwide. Its products include SCIZER for non-invasive subcutaneous fat reduction; ULTRAFORMER MPT, a solution for eyebrow lifting by coagulating skin tissue with a focused ultrasound stimulation system; ULTRAFORMER III, a high-intensity focused ultrasound surgical device used for tissue coagulation in eyelid lifting for skin tightening and improving subcutaneous tissue elasticity in the face (cheeks), abdomen, and thighs, as well as for addressing crow's feet, laugh lines, and neck wrinkles; INTRASURE, an aesthetics and healthcare multi-platform solution; FORSHAPE, an RF treatment system to increase metabolism, blood circulation, and tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used to coagulate skin tissue as a general electrosurgical instrument. It also provides CLATUU Alpha, a medical device that gradually reduces subcutaneous fat layers, particularly in areas with excessive fat accumulation, using low-temperature energy and negative pressure; Ulfit, a medical device used to improve skin elasticity and subcutaneous tissue in the abdomen and thighs by delivering HIFU energy; Refit, a medical device that uses RF and negative pressure to increase tissue temperature and blood flow, relieving pain in the treated area; AQUAPURE is the combination of four handpieces are respectively applied for acne suction, muscle pain relief, and other pain relief; and AQUAPURE II, a multi-functional facial and body care device. The company offers its products under the Classys, Cluederm, and the SKEDERM brands. It serves clinics, hospitals, and beauty salons. The company was incorporated in 2007 and is headquartered in Seoul, South Korea.
IPO date
Apr 03, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
242,938,965
34.87%
180,122,798
27.02%
141,803,242
40.96%
Cost of revenue
97,342,524
74,054,264
58,265,403
Unusual Expense (Income)
NOPBT
145,596,441
106,068,534
83,537,840
NOPBT Margin
59.93%
58.89%
58.91%
Operating Taxes
30,387,239
19,616,641
21,379,789
Tax Rate
20.87%
18.49%
25.59%
NOPAT
115,209,202
86,451,893
62,158,050
Net income
97,875,278
31.86%
74,225,203
-1.53%
75,378,647
72.08%
Dividends
(12,799,904)
(7,471,452)
(4,271,313)
Dividend yield
0.42%
0.31%
0.36%
Proceeds from repurchase of equity
(29,901)
(14,578,009)
(5,313,131)
BB yield
0.00%
0.60%
0.45%
Debt
Debt current
79,351,945
3,139,369
2,957,303
Long-term debt
12,546,451
63,716,796
66,039,931
Deferred revenue
125,000
207,422
690,712
Other long-term liabilities
1,169,099
10
(170)
Net debt
59,314,910
44,312,305
41,623,090
Cash flow
Cash from operating activities
102,800,407
64,631,972
54,754,505
CAPEX
(4,074,794)
(6,112,522)
(27,998,696)
Cash from investing activities
(82,247,361)
(48,157,758)
(91,994,853)
Cash from financing activities
(16,738,605)
(25,643,962)
21,055,239
FCF
51,492,672
20,162,199
45,123,787
Balance
Cash
159,359,372
137,837,865
113,223,567
Long term investments
(126,775,886)
(115,294,004)
(85,849,422)
Excess cash
20,436,538
13,537,721
20,283,982
Stockholders' equity
341,366,858
279,270,730
210,746,078
Invested Capital
524,613,410
335,798,284
258,725,300
ROIC
26.78%
29.08%
30.13%
ROCE
26.05%
30.36%
29.94%
EV
Common stock shares outstanding
64,158
64,405
64,703
Price
47,650.00
26.23%
37,750.00
105.16%
18,400.00
-2.13%
Market cap
3,057,139,374
25.74%
2,431,290,713
104.22%
1,190,529,698
-2.27%
EV
3,115,133,390
2,475,603,018
1,232,152,788
EBITDA
152,814,553
110,346,173
87,437,535
EV/EBITDA
20.39
22.43
14.09
Interest
2,040,647
1,958,684
2,609,848
Interest/NOPBT
1.40%
1.85%
3.12%